priors.science/reviews/hypertension-management

Hypertension Management

The current evidence on 20 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

20claims tracked
198primary papers reviewed
9 Aug 2026latest evidence review
Weeklyre-scored against new papers
9 Established · 11 Likely · 0 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
SGLT2 inhibitors reduce chronic kidney disease progressionRaas CKDEstablished93%11
Dual renin-angiotensin-aldosterone system blockade increases renal riskDrug ClassesEstablished91%8
Intensive systolic blood pressure below 120 reduces major cardiovascular eventsBP TargetsEstablished90%15
Sodium restriction lowers blood pressureLifestyleEstablished90%10
Finerenone reduces cardiovascular and renal eventsMra FinerenoneEstablished90%18
Calcium channel blocker versus angiotensin-converting enzyme inhibitor cardiovascular outcomesDrug ClassesEstablished89%8
Spironolactone superior fourth-line agent in resistant hypertensionResistant HTNEstablished89%11
Intensive blood pressure control reduces stroke in type 2 diabetesBP TargetsEstablished87%10
DASH diet plus sodium restriction lowers blood pressureLifestyleEstablished86%8
Finerenone reduces heart failure hospitalizationsMra FinerenoneEarly evidenceLikely84%14
Ambulatory blood pressure monitoring superior to office blood pressure for cardiovascular riskSpecial PopulationsLikely81%8
Primary aldosteronism is under-diagnosedPrimary AldosteronismLikely80%9
SGLT2 inhibitors lower nocturnal blood pressureSglt2 HTNLikely79%9
Beta-blocker inferior as first-line agentDrug ClassesLikely78%8
Aldosterone-to-renin ratio screening for primary aldosteronismPrimary AldosteronismLikely78%13
Renal denervation reduces systolic blood pressureResistant HTNLikely76%10
White-coat hypertension increases cardiovascular riskSpecial PopulationsLikely75%10
Low diastolic blood pressure J-curve risk in coronary artery diseaseBP TargetsLong-standingLikely73%9
Stopping renin-angiotensin-aldosterone system inhibitor has no benefit in chronic kidney diseaseRaas CKDLikely73%8
Intensive blood pressure treatment in frail elderlySpecial PopulationsLikely73%7
Track Hypertension Management.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.
Where the evidence sits in time
Early evidenceMost of this evidence is from the last two years.
Long-standingMost of this evidence is older than the rest of this field.